MedTrace Logo

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT07552779 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-27

No results posted yet for this study

Summary

Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.

The goal of this clinical trial is to compare how much of the study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food. The study will also measure how much ibuzatrelvir is in participants' blood after taking one type of the tablets dispersed in water and when one type of the tablets is taken with food. This study drug is taken by mouth.

Conditions

  • Coronavirus Disease 2019
  • Coronavirus Disease 2019 (COVID-19)
  • COVID-19 (Coronavirus Disease 2019)
  • Upper Respiratory Tract Infections
  • Respiratory Tract Infection
  • Respiratory Tract Diseases
  • COVID-19
  • COVID-19 Infection
  • COVID-19 SARS-CoV-2 Infection
  • Pneumonia
  • Lung Diseases

Interventions

DRUG

Ibuzatrelvir co-process API film coated tablet

original

DRUG

Ibuzatrelvir filmcoated tablet

new

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-13
Primary Completion
2026-06-03
Completion
2026-07-06
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07552779 on ClinicalTrials.gov